U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Vaping Veteran Supplies LLC - 545223 - 02/15/2018
  1. Warning Letters

WARNING LETTER

Vaping Veteran Supplies LLC MARCS-CMS 545223 —


Recipient:
Recipient Name
Jason F. Hunter
Vaping Veteran Supplies LLC

Spring Valley, CA 91979
United States

Issuing Office:
Center for Tobacco Products

United States


 

  

Black HHS-Blue FDA Logo

 

 

 
U.S. Food & Drug Administration
Center for Tobacco Products
10903 New Hampshire Avenue
Silver Spring, MD 20993 

 

FEB 15, 2018
 
VIA USPS and Electronic Mail
                       
Vaping Veteran’s Supplies LLC
Attn:Jason F. Hunter
P.O. Box 1333
Spring Valley, CA 91979
vapingvetsupplies@gmail.com              
 
WARNING LETTER
 
Dear Mr. Hunter:
 
The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed http://www.vvs619.com and determined that the e-liquid products listed there are offered for sale or distribution to customers in the United States. Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), as amended by the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)).
 
FDA has determined that a statement or representation made on the website http://www.vvs619.com regarding certain e-liquids violates section 301(tt) of the FD&C Act (21 U.S.C. 331(tt)) because it is directed to consumers and conveys, misleads, or would mislead consumers into believing that the tobacco products are approved by FDA.
 
Section 301(tt) Violation
 
FDA has determined that a statement or representation made on the website http://www.vvs619.com regarding certain e-liquid products violates section 301(tt) of the FD&C Act (21 U.S.C. 331(tt)), which prohibits:
 
“[m]aking any express or implied statement or representation directed to consumers with respect to a tobacco product, in a label or labeling or through the media or advertising, that either conveys, or misleads or would mislead consumers into believing, that—
(1)   the product is approved by the Food and Drug Administration;
(2)   the Food and Drug Administration deems the product to be safe for use by consumers;
(3)   the product is endorsed by the Food and Drug Administration for use by consumers; or
(4)   the product is safe or less harmful by virtue of—
(A)  its regulation or inspection by the Food and Drug Administration; or
(B)  its compliance with regulatory requirements set by the Food and Drug Administration…”
 
Specifically, certain e-liquid products are sold or distributed on the website to consumers in the United States with the statement “We use Nicotine that is FDA approved FDA Registration No. 11488791158, NDC# 055742-0003”: 3mg/mL Nicotine, 6mg/mL Nicotine, DIY 12mg/mL Nicotine, DIY 18mg/mL Nicotine, 24mg/mL Nicotine, and DIY 100mg/mL Nicotine. Because this statement or representation on your website is directed to consumers and conveys, misleads, or would mislead consumers into believing that the tobacco products are approved by FDA, they are in violation of section 301(tt) of the FD&C Act.
 
Misbranded Tobacco Products
 
FDA has also determined that certain e-liquid products are misbranded under section 903(a)(1) of the FD&C Act (21 U.S.C. § 387c(a)(1)) and/or section 903(a)(7)(A) of the FD&C Act (21 U.S.C. § 387c(a)(7)(A)). Section 903(a)(1) of the FD&C Act provides that a tobacco product is misbranded if its “labeling is false or misleading in any particular.” Section 903(a)(7) of the FD&C Act provides that a tobacco product distributed or offered for sale in any State is misbranded if its “advertising is false or misleading in any particular.” These e-liquid products are misbranded under section 903(a)(1) of the FD&C Act and/or section 903(a)(7)(A) of the FD&C Act as their labeling or advertising is false or misleading because it makes the statement or representation that the products are FDA approved.
 
Conclusion and Requested Actions
 
The violations discussed in this letter do not necessarily constitute an exhaustive list. You should immediately correct the violations that are referenced above, as well as violations that are the same as or similar to those stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act. 
 
It is your responsibility to ensure that your tobacco products and all related labeling and/or advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), and in any other media in which you advertise comply with each applicable provision of the FD&C Act and FDA’s implementing regulations.  Failure to ensure full compliance with the FD&C Act may result in FDA initiating further action without notice, including, but not limited to, civil money penalties, no-tobacco-sale orders, criminal prosecution, seizure, and/or injunction. Please note that adulterated and misbranded tobacco products offered for import into the United States are subject to detention and refusal of admission.
 
Please submit a written response to this letter within 15 working days from the date of receipt describing your corrective actions, including the dates on which you discontinued the violative labeling, advertising, sale, and/or distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. You can find the FD&C Act through links on FDA’s homepage at http://www.fda.gov.
 
Please note your reference number, RW1800815, in your response and direct your response to the following address:
 
DPAL-WL Response, Office of Compliance and Enforcement
FDA Center for Tobacco Products
c/o Document Control Center
Building 71, Room G335
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
 
If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.   
 
 
Sincerely,
/S/ 
Ann Simoneau, J.D.
Director
Office of Compliance and Enforcement
Center for Tobacco Products
 
 
VIA UPS and Electronic Mail
 
cc:
 
Vaping Veteran’s Supplies LLC
Attn: Jason Hunter
604 Galopago Street
Spring Valley, CA 91977
 
GoDaddy.com, LLC
abuse@godaddy.com
 
Amazon Technologies Inc.
abuse@amazonaws.com
 
 

 

Back to Top